NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Marino
Garcia, the company’s EVP and Chief Strategy Officer, will present a
corporate update at the Oppenheimer 27th Annual
Healthcare Conference on Tuesday, March 21, 2017 at 11:30 a.m. Eastern
Time at The Westin New York Grand Central in New York City.
A live webcast of the presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60
days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. The company
has pioneered discovery, research and development efforts on analogs of
uroguanylin, a naturally occurring and endogenous human GI peptide, for
the treatment of GI diseases and disorders. Synergy’s proprietary
uroguanylin analog platform includes one commercial product TRULANCE™
(plecanatide) and a second lead product candidate, dolcanatide. For more
information, please visit www.synergypharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005233/en/
Contacts
Synergy Pharmaceuticals Inc.
Gem Hopkins, 212-584-7610
VP,
Investor Relations and Corporate Communications
ghopkins@synergypharma.com
Source: Synergy Pharmaceuticals Inc.
Cet article Synergy Pharmaceuticals to Present at Oppenheimer 27th
Annual Healthcare Conference est apparu en premier sur EEI-BIOTECHFINANCES.